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Malformations of the heart represent the most common birth defect in human with an incidence of nearly 1% 
of all live  births1,2. There is a long and remarkable history of clinical recognition, therapeutic opportunities and 
understanding of the developmental, genetic and molecular origins of congenital heart diseases (CHDs)3. The 
etiology of the majority of CHDs, however, is poorly understood. Reasons are mainly due to their complexity 
because most of them are predicted to be multifactorial with elaborate genetic and environmental interactions 
in their  etiology3. One severe form of CHD is Tetralogy of Fallot (TOF), representing the most common form of 
cyanotic CHDs. TOF is characterized by four features, namely a narrowing of the right outflow tract (pulmonary 
stenosis), a ventricular septal defect (VSD), an overriding aorta and right ventricular  hypertrophy4. Recently, we 
showed an multigenic architecture of rare deleterious mutations in several genes, which discriminate isolated 
TOF cases from  controls5. The affected genes are connected in an interaction network and play important roles 
in apoptosis and cell growth as well as in the assembly of the sarcomere and in the neural crest or secondary heart 
field. Moreover, all these genes function during heart development, the postnatal period and  adulthood5. More 
recently, our findings have been confirmed by a larger cohort of  patients6. Considering that TOF is suggested 
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to be the result of altered proliferation, migration and differentiation of precardiac  cells7, the lack of in vitro 
sources for human cardiomyocytes (CMs) has significantly impeded the investigation of this heart malformation.
The recent development of the induced pluripotent stem cell (iPSC) technology allows, for the first time, 
the study of human diseases using patient-specific cells in vitro8. Defined protocols for directed differentiation 
of human iPSCs to CMs represent the first step towards establishing cardiac development and disease models 
in vitro9–12. CMs generated from patient-specific iPSCs (ps-iPSCs) have been widely used as models for several 
cardiac diseases including channelopathies, cardiomyopathies and congenital heart defects, along with isolated 
CHD with complex  genetics13–15. However, an in vitro model for TOF-specific CMs has not been described so far.
In this study, three ps-iPSC lines were generated from each of two well-characterized cases from our previ-
ously analyzed cohort of TOF  patients5. In addition, 12 iPSC lines from healthy relatives serving as controls were 
generated (Fig. 1A). The respective cell lines were further successfully differentiated to CMs. The clonal muta-
tional burden of the generated iPSCs was first analyzed by whole genome and transcriptome analysis. Moreover, 
there was shown to be potential disease-relevant differential gene expression between and across cardiomyocyte 
differentiation in TOF patients and healthy individuals. Overall, this study provides an in-depth understanding 
of cardiomyocyte differentiation and its transcriptional alterations in patients with TOF.
Results
Generation of iPSCs and differentiation to cardiomyocytes.  Somatic cells were isolated from skin 
biopsies of two TOF patients and three healthy relatives of two unrelated families (Fig. 1A,B). For each indi-
vidual, three independent iPSCs transduced from fibroblasts were established. The iPSCs are comparable to 
human embryonic stem cells (hESCs) and show the typical morphology of human iPSCs (Fig. 1C and Supple-
mentary Figs. S1–5A,B). At mRNA level, the investigated pluripotency markers also indicated the pluripotent 
cell state of all iPSC lines (Fig. 1B and Supplementary Figs. S1–5C). Efficiency of the cardiac differentiation of 
the iPSCs was further evaluated by counting beating embryoid bodies. RT-PCR and immunocytochemistry 
experiments showed that the iPSCs were pluripotent and had the potential to differentiate into cells of all three 
germ layers (Supplementary Figs. S1–5D,E). Overall, the applied protocol resulted in functional, spontaneously 
beating heart muscle cells with features characteristic of physiological CMs. After 15 days of differentiation, 
cells were treated with lactate-supplemented medium for four days to enrich for a purer cardiomyocyte popula-
tion (> 70%). The efficiency was validated by FACS-sorting against cTNT (cardiac troponin T). Forty days after 
induction of differentiation, iPSC-derived CMs showed a characteristic sarcomeric patterns, with no significant 
differences in differentiation efficiency between CMs of patients and controls in both families (Fig. 1D).
Sequencing of  iPSC samples.  As iPSCs offer a platform to study genetic mutations associated with a 
disease, Sanger sequencing was performed on all rare deleterious single nucleotide variations (SNVs), which 
had been found by targeted re-sequencing in the right ventricular tissue of TOF-01 and TOF-025. The sequence 
analysis of the iPSC lines confirmed that all mutations except one were present in the ps-iPSCs (Supplementary 
Tables S1–2). The confirmation of the mutations implied that the iPSCs would be suitable for studying the cel-
lular and molecular phenotype. Next, whole genome sequencing (WGS) was performed on blood as well as of 
pooled iPSC clones (three clones at d0) from patients and their respective relatives to check for possible sporadic 
mutations occurring during iPSC generation either due to potential reprogramming-associated mechanisms or 
as a feature of patient-specific genome  instabilty16. Individual clone-wise Sanger sequencing results were con-
firmed for known TOF gene mutations in the WGS samples of both blood and pooled iPSCs (Supplementary 
Tables S3-4). In addition, the differences between blood and iPSC samples were examined on a genome-wide 
scale based on local variations (SNVs as well as insertions and deletions, i.e., INDELs), copy number variations 
(CNVs) and structural variations (SVs).
In general, it was found that there was a very high overlap for all kinds of variations between the blood and 
iPSC samples (germline variants); only 1.6–3.0% SNVs in the pooled iPSC samples did not occur in the related 
blood samples (Fig. 2A and Supplementary Fig. S9). For these somatic variants, the sequencing coverage and 
base quality was compared as they may explain differences in the variant calling process. However, there was 
found to be a good correlation between blood and pooled iPSC samples over all individuals (Fig. 2B), indicating 
no sequencing-related bias. After initial variant calling, the raw variations were further filtered, which revealed 
almost no somatic and germline variations for healthy relatives (Fig. 2C and Supplementary Fig. S9).
Based on germline SNVs, 13 and 11 disease candidate genes were found in TOF-01 and TOF-02, respectively. 
In general, WGS resulted in different groups of candidate genes in both patients, which reflects the genetic 
heterogeneity of the disease. For TOF-01, the TOF-associated genes ERBB3 (Erb-B2 receptor tyrosine kinase 3) 
and TTN (titin) were again among the candidate genes. Genes affected in TOF-01 were significantly enriched for 
collagen-related pathways as well as for the extracellular matrix organization pathway and related Gene Ontol-
ogy (GO) terms. The affected genes in TOF-02 were significantly enriched for the glycosylphosphatidylinositol 
(GPI)-anchor-synthesis pathway and GO terms associated to metabolic processes. For INDELs or CNVs, no or 
no interesting hit, respectively, was found in the two TOF patients (Supplementary Fig. S9).
Clonal mutational burden by reprogramming of iPSC.  Focusing on disease-associated genes, which 
are potentially relevant for functional assays, further investigation was carried out for somatic and clonal vari-
ations that might interfere with disease modeling in iPSCs and derived CMs. For INDELs or larger variations, 
no relevant disease-related gene could be found. However, filtering for potential disease-related somatic SNVs 
revealed a few candidate genes (Fig. 2C). In addition to the results from WGS of the iPSC, clone-specific somatic 
mutations were identified in these genes based on the sequence read alignments of their individual RNA-seq 
data, which were also confirmed by Sanger sequencing (Fig. 2D and Supplementary Table S5).
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Figure 1.  Generation of iPSCs from TOF patients and healthy relatives and their differentiation to 
cardiomyocytes. (A) Families with TOF patients (indicated by a red heart) and healthy family members. 
For each generated cell line, the individual clone identifier is provided (n = 3 for corresponding individual). 
Moreover, it is indicated whether genomic DNA was taken from blood for whole genome sequencing and/
or from RV for targeted re-sequencing. (B) Generation of iPSCs and their differentiation to CMs. The gene 
expression of the pluripotency markers was also investigated at mRNA level by RT-PCR (here for iPSCs of 
TOF-01 exemplarily). The grouping of blots was cropped from different parts of the same gel, or from different 
gels. Uncropped blots are available in Supplementary Fig. S6. (C) Morphology of the generated iPSC colonies. 
Magnification 10×. Scale bar 100 µm. (D) Differentiation efficiency of CMs (each n = 3) at d15 and d60 between 
patients (light grey) and healthy relatives (dark grey). Cardiac differentiation efficiency is based on the percent of 
cTnT-positive CMs. CMs: cardiomyocytes; RV: right ventricle; TOF: Tetralogy of Fallot.
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Notably, a somatic mutation in TP53, encoding for the tumor protein P53, was found in two out of three iPSC 
clones of TOF-02 and not in the gDNA from blood of the patient. The identified mutation in TP53 is located 
Figure 2.  Identified candidate genes with somatic and/or germline single nucleotide variations in iPSCs of 
TOF patients and healthy relatives. (A) SNVs identified in blood and/or pooled iPSCs (n = 3). (B) Sequencing 
coverage and base quality for SNVs in blood (light red) or iPSCs only (cyan). (C) Filtering for disease candidate 
genes with somatic and germline SNVs. (D) Candidate genes with somatic SNVs. Whole genome sequencing 
was performed for pooled iPSCs and identified somatic SNVs were verified clone-wise (iPSC-specific) by whole 
transcriptome sequencing (RNA-seq). The individual somatic SNVs are marked in red. SNVs confirmed by 
Sanger sequencing are marked in bold. SNVs not verified by RNA-seq but confirmed by Sanger are marked by 
bold brackets. MAF: minor allele frequency; R: Spearman correlation; SNVs: single nucleotide variations; TPM: 
transcripts per kilobase million; WGS: whole genome sequencing.
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in the DNA binding domain of the protein (Fig. 3A), which was confirmed by Sanger sequencing (Fig. 3B). In 
general, iPSCs of TOF-02 have more variations compared to iPSCs of all other related or unrelated individuals 
(3.4 million vs. ~ 3.3 million SNVs and 1.49 million vs. ~ 1.47 million coding SNVs). Furthermore, expression of 
the gene TP53 was observed to be significantly decreased (Fig. 3C) as well as its encoded protein P53 (Fig. 3D) 
in both affected clones compared to the unaffected one. Moreover, ps-iPS cell culture revealed that the affected 
clones seemed to be growing faster (Fig. 3E). The major transcriptional target of P53 in response to cellular 
stress is P21, which is a key component in cell cycle control and  apoptosis17. As the DNA binding domain of 
P53 is affected by the mutation, P53 chromatin immunoprecipitation (ChIP) was performed at the promoter 
of P21 in all three iPSC clones of TOF-02. There was found to be significantly decreased binding of P53 at the 
promoter region of P21 in the affected clones (Fig. 3F). In line with this, the expression of P21 was also signifi-
cantly decreased in both clones (Fig. 3G). Furthermore, the impact of the clone-specific mutation in P53 on a 
global scale was evaluated by correlating fold changes of clone-specific gene expression profiles of P53 target 
genes. The targets were obtained from available datasets on P53 ChIP-Seq in  hESCs18 and ChIP-PET in primary 
cancer cells (HCT116)19. For both target gene sets, a strong correlation could only be found between the gene 
expression profiles of the two affected clones (Fig. 3H). This indicates that P53 target genes showed an altered 
gene expression profile at d0 in the affected clones. Moreover, these data clearly show that somatic mutations can 
alter the functional properties of both TOF-02-derived iPSCs and CMs. As this makes the cells inappropriate for 
studying the disease, we discarded TOF-02 for further analyses.
Correlation of gene expression in iPSCs and CMs to healthy and TOF heart tissue.  The expres-
sion profiles of iPSCs and CMs were correlated to corresponding gene expression in the right atrium and ven-
tricle (RA and RV, respectively) as well as in the left atrium and ventricle (LA and LV, respectively) of healthy 
individuals, as well as to the RV expression profile of TOF patients (Supplementary Fig. S11A). In general, cor-
relating expression profiles of iPSCs and CMs to heart tissue revealed nearly identical correlations for all origins. 
Thus, their profiles were combined for comparison to tissue profiles (Supplementary Fig. S11B). Overall, iPSCs 
correlated strongly with LA followed by LV, RA and finally, RV of healthy hearts. Furthermore, as expected, the 
correlation of expression profiles of iPSCs and derived CMs to tissues increased with the differentiation stage.
Common gene expression pattern during cardiac differentiation.  RNAseq analysis of iPSCs (d0) 
and CMs (d15 and d60) provided insights into general expression profiles characterizing the differentiation 
process from iPSCs to cardiomyocytes across all samples (Fig. 4). Of note, this data analysis included normaliza-
tion for cell composition. As expected, gene expression was altered from iPSCs to CMs at d15 and characterized 
by an up-regulation of genes associated with cardiac tissue development, cardiac ventricle morphogenesis and 
muscle cell differentiation. Up-regulated genes were significantly enriched for cardiac-, heart- or muscle-related 
GO terms and pathways.
Patient-specific  gene  expression  profiles  during  cardiac  differentiation.  In addition to study 
common expression profiles characterizing the differentiation process, we focused on patient-specific alterations 
during the differentiation of iPSCs to cardiomyocytes. These could highlight mechanism underlying a potential 
delay in differentiation or altered proliferation of cardiomyocytes eventually promoting the development of the 
structural defects observed in TOF.
Stage-specific alterations as well as dynamic changes across stages were analyzed. RNA-seq of iPSCs and CMs 
at d15 revealed 11 and 16 stage-specific genes, respectively, that were significantly differentially expressed between 
patient TOF-01 and healthy individuals (Fig. 4B). Among them are the cardiac-related gene GSTM1 (Glutathione 
S-Transferase Mu 1) (Supplementary Fig. S12A) and genes known to be cardiac relevant like TTR (transthyretin; 
cardiac amyloidosis and hypertrophic cardiomyopathy) and members of the apolipoprotein family including 
APOC3 (apolipoprotein C3; apolipoprotein C-III deficiency, Supplementary Fig. S12B,C). All of these genes 
are involved in various cellular transport activities with apolipoproteins being important components of many 
lipoproteins that are involved in cardiovascular  disease3,4,20,21. As expected, based on the principle component 
analysis (Supplementary Fig. S13), the patient-specific expression profile at d60 became even more pronounced. 
A fourfold higher number of significantly down-regulated genes were observed in patient-CMs. These genes 
were significantly enriched for cardiovascular-associated GO terms and pathways, such as cardiac conduction 
or cardiovascular system development (Fig. 4 and Supplementary Fig. S14).
In addition to a stage-wise comparison of diseased and healthy expression profiles, we found patient-specific 
expression changes during the differentiation process across stages (Fig. 4). These included the significant down-
regulation of several cardiac transcription factors (GATA factors, ISL1 (ISL LIM homeobox 1), HES1 (HES family 
BHLH transcription factor 1)), components of the NOTCH signaling cascade (e.g., JAG1 (jagged 1)), proteins 
relevant for cell–cell contacts (e.g., DSG2 (desmoglein 2)), and several genes coding for collagens. Beside this, 
genes handling ion transports were significantly up-regulated such as calcium or sodium channel genes (e.g., 
CACNA2D1 (calcium voltage-gated channel auxiliary subunit alpha2delta 1), SCN5A (sodium voltage-gated 
channel alpha subunit 5)). Overall, specific differentially expressed genes (DEGs) showed a clear separation in 
expression between patient and healthy relative during cardiomyocyte differentiation. Importantly, comparison 
of the observed alterations was in line with previous findings based on genetic mutations, differential expression 
or methylation observed in our overall TOF cohort (Fig. 4B)5,22.
Impact of variations on gene expression.  In general, genetic variations of iPSCs and blood were not 
reflected in the expression profiles of the affected genes, as none of the DEGs in the two patients versus its healthy 
parents overlap with genes harboring germline or somatic SNVs in the patient’s blood and/or respective clones 
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Figure 3.  Somatic mutation in TP53 in iPSC clones of patient TOF-02. (A) Multifunctional domains of P53 
(adapted from Robbins et al.38). The identified rare damaging SNV is located in the highly conserved DNA-
binding core domain. (B) Sanger sequencing results. (C) Expression of TP53 in the individual iPSC clones of 
TOF-02 measured using quantitative real-time PCR. Expression was measured in triplicates and normalized to 
HPRT. (D) The protein level of P53 in the individual iPSC clones of TOF-02. GAPDH was used as the internal 
control. The grouping of gels/blots cropped from different parts of the same gel. Uncropped blots are available 
in Supplementary Fig. S10. (E) The comparison of TOF-02 iPSC morphology. The cells were maintained and 
propagated in E8 medium. Scale bar 240 µm. (F) The relative fold change of P53 enrichment between P21 
positive region and negative region. (G) Expression of P21 in the individual iPSC clones of TOF-02 measured 
using quantitative real-time PCR. Expression was measured in triplicates (n = 3) and normalized to GAPDH. 
Significance was tested using a two-sided t-test. (H) Fold changes between clone-specific gene expression values 
of P53 target genes from ChIP-Seq in human embryonic stem cells (hESCs) and from ChIP-PET in HCT116 
cells. The blue line indicates the locally-weighted polynomial regression (lowess fit). R: Pearson correlation; 
SNV: single nucleotide variation; TPM: transcripts per kilobase million. *P-value < 0.05.
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:10921  | https://doi.org/10.1038/s41598-020-67872-z
www.nature.com/scientificreports/
(Supplementary Fig. S15). This also holds true for CMs of d15 but not fully for the CMs at d60. For the latter, four 
DEGs were found in TOF-01 compared to Father TOF-01 with rare damaging germline SNVs in TOF-01. Out 
of these genes, only DAAM2 (disheveled associated activator of morphogenesis 2) and FBLN2 (fibulin 2) har-
bored a differentially expressed isoform affected by a mutation. Both isoforms were decreased in ps-CMs at d60 
Figure 4.  Differential gene expression between and across cardiac differentiation. (A) Differentially expressed 
genes between TOF-01 and Father TOF-01 for iPSCs versus CMs at d15 and CMs at d15 versus d60 (n = 3 for 
each individual and stage except CMs at d15 with n = 2). Patient-specific gene expression alterations at a specific 
state are shown in black and commonly altered gene expression (i.e., in both TOF-01 and Father TOF-01) are 
given in gray. The depicted genes are filtered for cardiac system-related genes. Multiple genes (> 2) of the same 
gene family are indicated by an asterisk. Differential gene expression is based on expressed autosomal protein-
coding genes (adjusted P-value < 0.05, fold change > 2). (B) Overview of significantly differentially expressed 
genes (DEGs) in iPSCs and CMs of TOF-01 versus healthy individuals (Father TOF-01 and Mother TOF-02) 
and between differentiation stages of TOF-01 that are patient-specific (n = 3 for each individual and stage 
except CMs at d15 with n = 2 for TOF-01 and Father TOF-01). Cardiovascular-associated DEGs are listed and 
further marked if they overlap with findings based on genetic mutations, differential expression or methylation 
observed in our overall TOF  cohort5,22.
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(Fig. 5A). The SNV in FBLN2 was located in subdomain with a sevenfold decreased expression. The mutation in 
DAAM2 was not located in a specific domain; however, the expression was also sevenfold decreased in TOF-01.
The global impact of regulatory SNVs on transcriptional variations was further investigated by applying linear 
mixed effect models with transcripts filtered for SNVs in proximal promoter regions that overlap with transcrip-
tion factor binding sites (TFBS) (Fig. 5B). Overall, regulatory SNVs only had a minor effect on the transcriptional 
variation of the affected transcript, which is in line with the findings based on SNVs and DEGs at or between the 
different stages of cardiac differentiation. Considering highly expressed genes, most of the variance is explained 
by the differentiation state. This effect decreased for lower expressed transcripts. The family affiliation had only 
a small effect on transcriptional variation.
Discussion
Induced pluripotent stem cells and derived cardiomyocytes are a valuable resource to model and to study diseases 
such as heart  malformation13,23. In this study, ps-iPSCs were successfully generated and further differentiated into 
CMs to gain insights into TOF. Maturity and purity of CMs as well as their genetic integrity are methodological 
hurdles of iPSC applications. Simulations suggest there is a magnitude higher mutation intensity in iPSCs than 
the background mutation rate in culture due to induced reprogramming  stress24. Although there are only small 
differences in the total numbers and types of variations among the different reprogramming methods, albeit 
most of the occurring variations are  benign25. In general, differences in functional assays of iPSCs can be driven 
Figure 5.  Differential gene expression and impact of variations. (A) Expression level of FBLN2 and DAAM2 
in iPSCs and CMs of TOF patients and healthy individuals (n = 3 for each individual except CMs at d15 with 
n = 2 for TOF-01 and Father TOF-01; n = 0 for TOF-02 & sister TOF-01 at d15 & d60) as well as in the right 
ventricle of TOF patients and normal heart individuals. Both transcripts, which harbor mutations in TOF-01, 
were significantly differentially expressed between TOF-01 and Father TOF-01 in CMs at d60. (B) Impact of 
regulatory SNVs on transcriptional alterations. Linear mixed models were applied to all, highly and low/middle 
expressed autosomal protein-coding transcripts harboring I) SNVs called by WGS in the blood samples (‘GT 
blood’), II) SNVs called by WGS and confirmed by RNA-seq in the blood samples (‘RNAseq GT blood’) and III) 
SNVs called by WGS in the pooled iPSC samples and confirmed by RNA-seq of the individual clones (‘RNA-seq 
GT Pooled iPSCs’). GT: genotype; SNVs: single nucleotide variations.
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by genetic variability, either induced during reprogramming or as a feature of genomic instability underlying 
the  disease26. Thus, to investigate somatic and clonal variations that might interfere with the disease modeling 
in vitro, we performed whole genome and transcriptome analyses from blood and/or iPSCs of the TOF patients 
and healthy relatives. Surprisingly, in two out of three clones of TOF-02, a somatic mutation was found in TP53, 
which encodes for the tumor protein P53. This protein acts as a tumor suppressor, meaning that it regulates cell 
division by preventing cells from growing and dividing too fast or in an uncontrolled way. Somatic mutations in 
the TP53 gene are some of the most frequent alterations in human  cancers27. In iPSCs, P53 is demonstrated to be 
required for maintaining genome integrity and it is expected to prevent accumulation of reprogramming-induced 
 mutations24,28. In line with this, iPSCs of TOF-02 have more variations compared to iPSCs of all other related or 
unrelated individuals. Moreover, it was shown that in human ESCs the TP53 mutant allelic fraction increased 
with passage number, which suggests that there is a selective advantage though P53  mutations29. Here, we dis-
carded cells of TOF-02 for studying TOF; however, it clearly shows that supposedly disease-relevant somatic 
mutations can occur in iPSCs despite their low probability. Conclusions from the present study are limited by 
their sample size and it will be highly interesting to evaluate in further studies the probability of somatic muta-
tions and genomic instability as an underlying feature of TOF.
During differentiation, an increasing number of DEGs was found between TOF-01 and healthy individuals. 
At the latest stage, several collagen-related genes were found to be differentially expressed. These genes harbor 
no mutations. However, it clearly shows that collagen-related genes are in general affected by genetic and/or 
transcriptional alterations in TOF. In addition to collagen-related genes, other potential disease-relevant ones 
were identified. For example, BICC1 and MYH11 were found to be down-regulated in CMs at d60 of TOF-01. 
The smooth muscle myosin MYH11 is usually absent from the heart but present in parts of the vasculature 
including the  aorta30. The RNA-binding protein BICC1 acts as a negative regulator of the Wnt signaling pathway 
and might be involved in regulating gene expression during embryonic  development31. It has been shown that 
rare deletions in TOF patients are significantly enriched for genes of the Wnt signaling  pathways4. In addition 
to differential expression between two individuals at a certain differentiation stage, differential expression was 
observed across the different stages of maturation, specific for the particular individual or comparable with 
others. In general, genes which were specific differentially expressed between d15 and d0 in TOF-01 or Father 
TOF-01 were not enriched for cardiac system-related GO terms and/or pathways. In contrast, there was a clear 
difference in patient-specific DEGs compared to its healthy relative during cardiac differentiation. In fact, there 
was a higher number of down-regulated genes in CMs of TOF-01 at d60 versus d15 and moreover, these genes 
were enriched for cardiac system-related GO terms and pathways. Overall, the expression profiles of derived 
CMs differ increasingly between TOF-01 and Father TOF-01 and further segregate during cardiac differentiation, 
with clear differences regarding cardiac system-related expression at the later stages.
It was also checked whether genetic variations of iPSCs and derived CMs are reflected in the expression pro-
files of the affected genes. Globally, our approach is limited to SNVs in proximal promoter regions that overlap 
with TFBS. However, like others, we did not observe a correlation between genetic variations and expression 
 alterations5,32. At d60, DEGs with potential disease-causing mutations in TOF-01, such as FBLN2 and DAAM2, 
were found in TOF-01 CMs. DAAM2 is co-required for myocardial maturation and sarcomere  assembly33 and 
together with DAAM1 (disheveled associated activator of morphogenesis 1), it nucleates actin and mediates 
Wnt-induced cytoskeletal  changes33. FBLN2 has an important role in cardiovascular development and smooth 
muscle cell migration und is also one of the candidate genes with deleterious variants in patients with down-
syndrome-associated atrioventricular septal  defects34. Furthermore, it is involved in the vascular endothelial 
growth factor-A (VEGF) signaling pathway, which is known to play a role in atrioventricular valvuloseptal 
 morphogenesis34. VEGF and subsequent Notch signaling is important in cardiac outflow tract development 
and alterations can lead to abnormal development of myocardial  structures35. Moreover, it is suggested that low 
expression VEGF haplotype increases the risk for  TOF36.
In order to give insights into the molecular changes underlying the etiology of TOF, the establishment of ps-
iPSCs and their differentiation to cardiomyocytes is assumed to be a valuable model. The results of this study are 
merely based on three clones each from one patient and healthy relatives; however, they show clear transcriptional 
differences in CMs of the patient, which needs to be verified by follow-up studies with more cases. Moreover, 
modeling TOF is challenging as it is characterized by several malformations at the organ level occurring at 
once. Heart organoids or other three-dimensional models might therefore be better choices to investigate severe 
heart malformations. Nevertheless, our results based on monolayer CMs cultures, which model the muscular 
rather than the structural phenotype, are promising for further investigations. Moreover, they contribute to the 
further understanding of this disease, for which an in vitro model has not been described so far, neither as 2D 
or 3D model. Lastly, we used healthy relatives instead of isogenic lines as controls for this study. The rationale 
behind is that TOF is a complex oligogenic disorder with unknown exact genetic  causes3. Moreover, isogenic 
lines introduce variability due to gene editing off-target events and stress caused by additional rounds of culture 
selection, whereas cell lines from patients and relatives carrying the same genetic background more accurately 
mirrors the real  situation37.
In summary, iPSC technology was employed in the present study to model and to study TOF-specific cardio-
myocytes for the first time in vitro. Indeed, clear transcriptional differences between CMs of the patient and its 
healthy relative were observed, in particular at the later stages of cardiac differentiation. Our findings provide 
novelty into the transcriptional landscape of TOF and potentially improve our understanding of right ventricular 
heart failure, which is the major long-term phenotype of TOF patients.
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Methods
Study participants and ethical statement.  Skin biopsies for iPSC generation were obtained from three 
members of family 1 (from the patient TOF-01 and from his unaffected father and sister) and two members of 
family 2 (from the patient TOF-02 and her unaffected mother) (Fig. 1A). Further, blood samples for DNA analy-
sis were taken from the three members of family 1 as well as family 2 as described  previously5. Cardiac biopsies 
from the right ventricle were taken from the two TOF patients as described  previously5. In addition, biopsies 
were taken from eight other TOF patients and 16 healthy individuals. The local institutional review board of the 
Charité – Universitätsmedizin Berlin approved the study and informed consent was obtained from all partici-
pants or guardians. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Generation of  iPSCs and differentiation  into  cardiomyocytes.  iPSCs were generated from skin 
biopsies of two TOF patients and three healthy relatives using STEMCCA system, containing all four repro-
gramming factors OCT4, SOX2, KLF4, and c-MYC. For each individual, three iPSC clones were  generated12. 
The cardiac differentiation was carried out by manipulating Wnt-signaling, applying small molecules under fully 
defined conditions. CMs were selected after day 15 using lactate-supplemented medium for four days.
Whole genome and transcriptome sequencing.  Genomic DNA (gDNA) from blood of patients and 
healthy relatives was extracted using QIAamp DNA Blood Midi Kit (Qiagen). gDNA from three iPSC clones was 
pooled for each individual before library preparation and sequencing. Each sample was prepared according to 
the Illumina TruSeq DNA sample preparation guide to obtain a final library of 300–400 bp average insert size. 
Whole genome sequencing (WGS) of the blood and pooled iPSCs samples was performed by Macrogen using 
Illumina HiSeq X (2 × 150 bp paired-end sequencing, 30 × coverage). On average, sequencing resulted in 77 mil-
lion reads per sample.
Total RNA was isolated and purified to get poly(A) RNA. The RNA libraries were prepared with the ScriptSeq 
v2 RNA-Seq Library Preparation Kit (Illumina). Paired-end sequencing was performed on either HiSeq 2,500 
(2 × 51 bp) or NextSeq (2 × 76 bp) (Illumina). All kits were applied according to the manufacturer’s instructions. 
On average, mRNA sequencing (RNA-seq) resulted in 65 million reads per sample.
Statistics.  General bioinformatics and statistical analyses were conducted using R (including Bioconductor 
packages) and Perl.
Data access.  RNA-seq data of iPSCs and derived CMs are available from the Gene Expression Omnibus 
(GEO) repository at NCBI (accession number GSE111230).
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